

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**ID 821 Anamorelin for treating cachexia and anorexia in people with non-small-cell lung cancer (Batch 48)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees were concerned that patients who are referred at an earlier stage to palliative care services could be excluded from receiving anamorelin if the drug is restricted to use within oncological services

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

NICE technology appraisal guidance does not typically restrict the setting in which a drug can be prescribed, unless such a restriction is included in the marketing authorisation or is proposed as important by consultees. This is not anticipated to be an equality issue that can be addressed by the committee within its recommendations, but may need further assessment during the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?

No additional stakeholders related to potential equality issues were identified.

**Approved by Associate Director (name):** Helen Knight

**Date:** 23/11/2016